Results 261 to 270 of about 45,189 (317)
Some of the next articles are maybe not open access.
SULPHASALAZINE: A ‘NEW’ ANTIRHEUMATIC DRUG
Rheumatology, 1984Sulphasalazine was first introduced for the treatment of rheumatoid arthritis in 1942. Following initial enthusiasm, interest waned until 1978 when a large open study suggested that it might have a 'second-line effect'. Since then further studies have confirmed this effect and once again rheumatologists are starting to use sulphasalazine in the ...
T, Pullar, H A, Capell
openaire +2 more sources
Disease-Modifying Antirheumatic Drugs
The Journal of Hand Surgery, 2009S T m f p c In B ri ef ISEASE-MODIFYING ANTIRHEUMATIC drugs (DMARDs) reduce the extent to which rheumatoid arthritis (RA) damages bone and carilage and reduce the disability that results from it. ll patients with RA should receive one or more MARDs as soon as the diagnosis of RA is estabished, because evidence suggests that the long-term utcome is ...
openaire +2 more sources
The evaluation of antirheumatic drugs
Current Medical Research and Opinion, 1973SummaryThe available methods of evaluation of an antirheumatic compound in a clinical trial situation are discussed. The techniques of single-blind and double-blind studies are described and their respective merits analysed. Proposed new techniques for the measurement of joint inflammation are reviewed.
P, Lee +3 more
openaire +2 more sources
Anti-inflammatory and Antirheumatic Drugs
Annals of Internal Medicine, 1981Excerpt Meclofenamate sodium (Meclomen; Parke-Davis, Morris Plains, New Jersey), a nonsteroidal anti-inflammatory agent of the fenamate group, has recently been approved by the U.S.
openaire +2 more sources
[Monitoring of antirheumatic drugs].
Revue medicale suisse, 2022Regular blood monitoring allows for treatment adjustments and early detection or even prevention of some side effects of antirheumatic dugs. Guidelines may vary between national societies for rheumatology, but largely recommend baseline screening followed by regular blood tests depending on the specific drug and duration of treatment.
Romain, Guemara, Ilias, Lazarou
openaire +1 more source
Hepatotoxicity related to antirheumatic drugs
Nature Reviews Rheumatology, 2011Antirheumatic agents are among commonly used drugs associated with adverse hepatic reactions. Sulfasalazine and azathioprine are among the most important causes of acute hepatotoxicity. Because such a large number of people take NSAIDs, even the rare occurrence of hepatotoxicity from these agents might contribute substantially to the total burden of ...
openaire +2 more sources
Inpharma Weekly, 1993
Nature appears to be competing well against the laboratory as a source of potential antirheumatic drugs. Up-to-date studies of both natural agents and new chemical entities (NCEs) were presented at the 5th Interscience World Conference on Inflammation, Antirheumatics, Analgesics and Immunomodulators in Geneva, Switzerland, last month.
openaire +1 more source
Nature appears to be competing well against the laboratory as a source of potential antirheumatic drugs. Up-to-date studies of both natural agents and new chemical entities (NCEs) were presented at the 5th Interscience World Conference on Inflammation, Antirheumatics, Analgesics and Immunomodulators in Geneva, Switzerland, last month.
openaire +1 more source
Drug therapy reviews: Antirheumatic agents
American Journal of Health-System Pharmacy, 1979The pathophysiology, symptoms and drug treatment of rheumatic disease are reviewed. Antirheumatic drugs reviewed are salicylates (including aspirin, sodium salicylate, choline salicylate, choline magnesium salicylate, salsalate), phenylpropionic acid derivatives (fenoprofen, ibuprofen, naproxen), indole derivatives (sulindac, tolmetin and indomethacin),
openaire +2 more sources
Antirheumatic drug side-effects alert
Nursing Standard, 1993Potentially fatal side-effects of slow acting antirheumatic drugs (SAARDs) mean comparative drug trials are needed to answer 'fundamental' questions about their longterm efficacy, says a report in Drug and Therapeutics Bulletin.
openaire +2 more sources
Disease-modifying antirheumatic drugs
20111. Disease-Modifying Antirheumatic Drug (DMARD) Designations in RA a. A drug must change the course of the disease for at least 1 year b. Change evidenced by one of the following i. Sustained improvement in physical function ii. Decreased inflammatory synovitis iii. Slowing or prevention of structural joint damage c.
openaire +2 more sources